SECTRAL Drug Patent Profile

Which patents cover Sectral, and what generic alternatives are available?

Sectral is a drug marketed by Promius Pharma and is included in one NDA.

The generic ingredient in SECTRAL is acebutolol hydrochloride. There are nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the acebutolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sectral

A generic version of SECTRAL was approved as acebutolol hydrochloride by ANI PHARMS on October 18^th, 1995.

Summary for SECTRAL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for SECTRAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Promius Pharma	SECTRAL	acebutolol hydrochloride	CAPSULE;ORAL	018917-001	Dec 28, 1984		DISCN	Yes	No
Promius Pharma	SECTRAL	acebutolol hydrochloride	CAPSULE;ORAL	018917-003	Dec 28, 1984		DISCN	Yes	No

International Patents for SECTRAL

See the table below for patents covering SECTRAL around the world.

Country	Patent Number	Title	Estimated Expiration
Malaysia	7400060	BENZENE DERIVATIVES
Austria	292671
France	7616
Finland	49290

What is the current investment scenario and fundamentals of SECTRAL?

Last updated: February 10, 2026

SECTRAL (propranolol) is a beta-blocker indicated for hypertension, angina, arrhythmias, and migraine prophylaxis. Its patent expired decades ago, and the drug is manufactured generically. The investment landscape revolves around ongoing patent expirations, market competition, regulatory environment, and manufacturing dynamics.

How does the market landscape affect SECTRAL's investment potential?

SECTRAL's sales have stabilised amidst widespread generic competition. The key factors include:

• Patent Status: Patent expired in most regions by the late 1980s, resulting in a saturated generics market.
• Market Share: Historically, propranolol held significant market share; however, newer beta-blockers with improved side-effect profiles have eroded its dominance.
• Global Sales: Estimated at approximately $100–150 million annually at peak, now trending downward due to competition and generics.

Competitive Pricing Dynamics and Market Penetration

Generic commoditization suppresses profit margins. The price per unit has declined by approximately 80% over the past two decades. Generic manufacturers such as Teva, Sandoz, and Mylan dominate supply.

Regulatory and Reimbursement Landscape

Regulatory hurdles are minimal; approvals are straightforward, given the drug's established safety profile. Reimbursement policies vary but tend to favor generic pricing, limiting revenue upside.

What are the manufacturing and supply chain considerations?

Production costs for propranolol are low, with complex synthesis processes dating back decades. The drug's high biosimilarity means manufacturing capacity is widely available, limiting supply constraints. Patent expirations have led to multiple overlapping sources, keeping prices depressed.

Supply Chain Risks

While manufacturing is established, risks include:

• Regulatory scrutiny over quality control.
• Political or trade restrictions affecting supply, particularly in high-growth markets like India and China.

What are the future prospects for SECTRAL?

Potential growth avenues are limited:

• Line Extensions: No recent patent or formulation innovations.
• New Indications: Some research into propranolol for post-traumatic stress disorder (PTSD) and certain cancers is ongoing but lacks regulatory approval.
• Market Growth: Overall demand remains steady but declining due to entry of newer, targeted therapies.

Investment Implication

The core value in SECTRAL today lies in its status as a well-established, low-cost generic. Margins are thin with minimal growth prospects. Investors should view it as a stable cash flow generator rather than an asset with significant growth potential.

What financial metrics are relevant?

Since proprietary rights have expired, revenue streams depend on:

• Average Selling Price (ASP): Declining trend.
• Market Share: Stable but decreasing.
• Production Costs: Low and stable.
• Regulatory Costs: Minimal ongoing expenses.

Margins are compressed, with profit margins typically below 10%. Return on investment hinges on manufacturing efficiency and market share retention.

What regulatory and legal factors influence investment?

• Patent Expiry: Almost complete; no patent protection remains.
• Regulatory Changes: Generally stable for generics.
• Legal Risks: Few, barring patent disputes or quality lawsuits.

Summary

SECTRAL is a mature, low-cost generic with declining sales in a highly competitive environment. It has minimal regulatory hurdles with stable supply chains. Investment considerations center on cash flow stability rather than growth or innovation.

---

Key Takeaways

• The patent for propranolol has long expired; SECTRAL's sales are influenced primarily by generic competition.
• Margins are slim due to aggressive pricing and market saturation.
• Manufacturing costs are low, and supply is abundant.
• Future growth potential is limited without new indications or formulations.
• The investment value lies in steady cash flow, not expansion.

---

FAQs

1. Why has SECTRAL's market share declined?
Newer beta-blockers with fewer side effects and better profiles have replaced propranolol in some indications, reducing SECTRAL's market share.

2. Are there any regulatory hurdles to manufacturing generic propranolol?
No, given the drug's established safety profile and patent expiration, regulatory processes are straightforward.

3. What are the main risks for investors in SECTRAL?
Market saturation, continued low pricing, and the absence of growth opportunities. Supply chain disruptions are a lesser concern due to widespread manufacturing.

4. Can SECTRAL be leveraged for new indications?
Research into off-label uses exists, but regulatory approval for new indications is unlikely and would require significant investment.

5. How does pricing impact profitability?
Price erosion due to generic competition compresses margins, making cost control essential for profitability.

---

References

[1] IQVIA, Global Pharma Market Data 2022
[2] FDA Drug Approvals and Patent Status Reports
[3] IMS Health, Prescription Trends 2021